Table 3.

Efficacy, coverage and adherence values used in base-case analysis

Intervention	Efficacy	Coverage		Provider adherence		Patient adherence
		Current	Target	Current	Target	Current	Target
Drugs providing sustained headache relief
ASA 1,000 mg	39% [21]	80%	90%	100%	100%	80%	90%
		(Zambia 50%)
Sumatriptan 50 mg	35% [19]	2%	(Zambia 80%)	75%	88%	56%	78%
		(Zambia 1%)
Almotriptan 12.5 mg	45% [20]	0%		75%	88%	56%	78%
Drugs averting migraine attacks
Propranolol 160 mg	28% [22]	3%	30%	75%	88%	71%	86%
Topiramate 100 mg	40% [23]	1%		75%	88%	60%	80%
Amitriptyline 100 mg	44% [24]	3%		75%	88%	42%	71%